Common threads in atrial fibrillation and heart failure

Heart Failure Clinics

Volumn 9, Issue 4, 2013, Pages 373-383

  Grace, Andrew A ^a,b   Narayan, Sanjiv M ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b PAPWORTH HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atrial fibrillation; Chronic heart failure; Genetics; Genomics; Remodeling; Systems biology

Indexed keywords

ANTIARRHYTHMIC AGENT; DRONEDARONE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; POTASSIUM CHANNEL BLOCKING AGENT; SOTALOL;

ABLATION THERAPY; ARRHYTHMOGENESIS; BODY MASS; CALCIUM SIGNALING; CARDIOVASCULAR RISK; CHANNELOPATHY; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); CONGESTIVE CARDIOMYOPATHY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; EUROPE; FAMILIAL DISEASE; FATTY ACID OXIDATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE FUNCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; METABOLIC DISORDER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PHENOTYPE; PREVALENCE; REVIEW; RISK ASSESSMENT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; UNITED STATES;

ATRIAL FIBRILLATION; CHRONIC HEART FAILURE; GENETICS; GENOMICS; REMODELING; SYSTEMS BIOLOGY;

ATRIAL FIBRILLATION; HEART CONDUCTION SYSTEM; HEART FAILURE; HUMANS; PREVALENCE; RISK FACTORS; WORLD HEALTH;

EID: 84884344969     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2013.07.011     Document Type: Review

References (105)

1. Anter E., Jessup M., Callans D.J. Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. Circulation 2009, 119(18):2516-2525.
2. Carson P.E., Johnson G.R., Dunkman W.B., et al. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. Circulation 1993, 87(Suppl 6):VI102-VI110.
3. Stevenson W.G., Stevenson L.W. Atrial fibrillation in heart failure. NEngl J Med 1999, 341(12):910-911.
4. Ben Morrison T., Jared Bunch T., Gersh B.J. Pathophysiology of concomitant atrial fibrillation and heart failure: implications for management. Nat Clin Pract Cardiovasc Med 2009, 6(1):46-56.
5. Benjamin E.J., Chen P.S., Bild D.E., et al. Prevention of atrial fibrillation: report from a National Heart, Lung, and Blood Institute workshop. Circulation 2009, 119(4):606-618.
6. Tsang T.S., Gersh B.J., Appleton C.P., et al. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. JAm Coll Cardiol 2002, 40(9):1636-1644.
7. Ellinor P.T., Lunetta K.L., Albert C.M., et al. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet 2012, 44(6):670-675.
8. Magnani J.W., Rienstra M., Lin H., et al. Atrial fibrillation: current knowledge and future directions in epidemiology and genomics. Circulation 2011, 124(18):1982-1993.
9. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. JAm Coll Cardiol 2013, [Epub ahead of print].
10. Braunwald E. Heart failure. JACC Heart Fail 2013, 1:1-20.
11. Lee D.S., Gona P., Vasan R.S., et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute. Circulation 2009, 119(24):3070-3077.
12. Darby A.E., Dimarco J.P. Management of atrial fibrillation in patients with structural heart disease. Circulation 2012, 125(7):945-957.
13. Wang T.J., Larson M.G., Levy D., et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003, 107(23):2920-2925.
14. Olsson L.G., Swedberg K., Ducharme A., et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart Failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. JAm Coll Cardiol 2006, 47(10):1997-2004.
15. Nattel S., Maguy A., Le Bouter S., et al. Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation. Physiol Rev 2007, 87(2):425-456.
16. Aiba T., Tomaselli G.F. Electrical remodeling in the failing heart. Curr Opin Cardiol 2010, 25(1):29-36.
17. Barth A.S., Kumordzie A., Frangakis C., et al. Reciprocal transcriptional regulation of metabolic and signaling pathways correlates with disease severity in heart failure. Circ Cardiovasc Genet 2011, 4(5):475-483.
18. Michael G., Xiao L., Qi X.Y., et al. Remodelling of cardiac repolarization: how homeostatic responses can lead to arrhythmogenesis. Cardiovasc Res 2009, 81(3):491-499.
19. Grace A.A., Roden D.M. Systems biology and cardiac arrhythmias. Lancet 2012, 380(9852):1498-1508.
20. Tinetti M.E., Fried T.R., Boyd C.M. Designing health care for the most common chronic condition--multimorbidity. JAMA 2012, 307(23):2493-2494.
21. Go A.S., Mozaffarian D., Roger V.L., et al. Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation 2013, 127(1):e6-e245.
22. Miyasaka Y., Barnes M.E., Gersh B.J., et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006, 114(2):119-125.
23. Miyasaka Y., Barnes M.E., Gersh B.J., et al. Incidence and mortality risk of congestive heart failure in atrial fibrillation patients: a community-based study over two decades. Eur Heart J 2006, 27(8):936-941.
24. Stefansdottir H., Aspelund T., Gudnason V., et al. Trends in the incidence and prevalence of atrial fibrillation in Iceland and future projections. Europace 2011, 13(8):1110-1117.
25. Savelieva I., John Camm A. Atrial fibrillation and heart failure: natural history and pharmacological treatment. Europace 2004, 5(Suppl 1):S5-S19.
26. Wakili R., Voigt N., Kaab S., et al. Recent advances in the molecular pathophysiology of atrial fibrillation. JClin Invest 2011, 121(8):2955-2968.
27. Lopez-Otin C., Blasco M.A., Partridge L., et al. The hallmarks of aging. Cell 2013, 153(6):1194-1217.
28. Fatkin D., MacRae C., Sasaki T., et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. NEngl J Med 1999, 341(23):1715-1724.
29. Olson T.M., Michels V.V., Ballew J.D., et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. JAMA 2005, 293(4):447-454.
30. Darbar D., Kannankeril P.J., Donahue B.S., et al. Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation. Circulation 2008, 117(15):1927-1935.
31. Kathiresan S., Srivastava D. Genetics of human cardiovascular disease. Cell 2012, 148:1242-1257.
32. Gudbjartsson D.F., Arnar D.O., Helgadottir A., et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature 2007, 448(7151):353-357.
33. Cappola T.P., Dorn G.W. Clinical considerations of heritable factors in common heart failure. Circ Cardiovasc Genet 2011, 4(6):701-709.
34. O'Rahilly S. Human genetics illuminates the paths to metabolic disease. Nature 2009, 462(7271):307-314.
35. Kenchaiah S., Evans J.C., Levy D., et al. Obesity and the risk of heart failure. NEngl J Med 2002, 347(5):305-313.
36. Wang T.J., Parise H., Levy D., et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004, 292(20):2471-2477.
37. Tedrow U.B., Conen D., Ridker P.M., et al. The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation: the WHS (Women's Health Study). JAm Coll Cardiol 2010, 55(21):2319-2327.
38. Rosenberg M.A., Gottdiener J.S., Heckbert S.R., et al. Echocardiographic diastolic parameters and risk of atrial fibrillation: the Cardiovascular Health Study. Eur Heart J 2012, 33(7):904-912.
39. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002, 415(6868):219-226.
40. Schotten U., Verheule S., Kirchhof P., et al. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev 2011, 91(1):265-325.
41. Byrd G.D., Prasad S.M., Ripplinger C.M., et al. Importance of geometry and refractory period in sustaining atrial fibrillation: testing the critical mass hypothesis. Circulation 2005, 112(Suppl 9):I7-I13.
42. Bode F., Sachs F., Franz M.R. Tarantula peptide inhibits atrial fibrillation. Nature 2001, 409(6816):35-36.
43. Kalifa J., Jalife J., Zaitsev A.V., et al. Intra-atrial pressure increases rate and organization of waves emanating from the superior pulmonary veins during atrial fibrillation. Circulation 2003, 108(6):668-671.
44. John B., Stiles M.K., Kuklik P., et al. Reverse remodeling of the atria after treatment of chronic stretch in humans: implications for the atrial fibrillation substrate. JAm Coll Cardiol 2010, 55(12):1217-1226.
45. Mayr M., Yusuf S., Weir G., et al. Combined metabolomic and proteomic analysis of human atrial fibrillation. JAm Coll Cardiol 2008, 51(5):585-594.
46. Barth A.S., Tomaselli G.F. Cardiac metabolism and arrhythmias. Circ Arrhythm Electrophysiol 2009, 2(3):327-335.
47. Reilly S.N., Jayaram R., Nahar K., et al. Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: implications for the antiarrhythmic effect of statins. Circulation 2011, 124(10):1107-1117.
48. Friedrichs K., Klinke A., Baldus S. Inflammatory pathways underlying atrial fibrillation. Trends Mol Med 2011, 17(10):556-563.
49. Li J., Solus J., Chen Q., et al. Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm 2010, 7(4):438-444.
50. Mihm M.J., Yu F., Carnes C.A., et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001, 104(2):174-180.
51. Adam O., Frost G., Custodis F., et al. Role of Rac1 GTPase activation in atrial fibrillation. JAm Coll Cardiol 2007, 50(4):359-367.
52. Oka T., Hikoso S., Yamaguchi O., et al. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature 2012, 485(7397):251-255.
53. Konstantinidis K., Kitsis R.N. Cardiovascular biology: escaped DNA inflames the heart. Nature 2012, 485(7397):179-180.
54. Bayeva M., Gheorghiade M., Ardehali H. Mitochondria as a therapeutic target in heart failure. JAm Coll Cardiol 2013, 61(6):599-610.
55. El-Armouche A., Boknik P., Eschenhagen T., et al. Molecular determinants of altered Ca2+ handling in human chronic atrial fibrillation. Circulation 2006, 114(7):670-680.
56. Wijffels M.C., Kirchhof C.J., Dorland R., et al. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995, 92(7):1954-1968.
57. Ausma J., Wijffels M., Thone F., et al. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation 1997, 96(9):3157-3163.
58. Du J., Xie J., Zhang Z., et al. TRPM7-mediated Ca2+ signals confer fibrogenesis in human atrial fibrillation. Circ Res 2010, 106(5):992-1003.
59. Jahangir A., Lee V., Friedman P.A., et al. Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study. Circulation 2007, 115(24):3050-3056.
60. Spach M.S. Mounting evidence that fibrosis generates a major mechanism for atrial fibrillation. Circ Res 2007, 101(8):743-745.
61. Kistler P.M., Sanders P., Fynn S.P., et al. Electrophysiologic and electroanatomic changes in the human atrium associated with age. JAm Coll Cardiol 2004, 44(1):109-116.
62. Stiles M.K., John B., Wong C.X., et al. Paroxysmal lone atrial fibrillation is associated with an abnormal atrial substrate: characterizing the "second factor.". JAm Coll Cardiol 2009, 53(14):1182-1191.
63. Roberts-Thomson K.C., Stevenson I.H., Kistler P.M., et al. Anatomically determined functional conduction delay in the posterior left atrium relationship to structural heart disease. JAm Coll Cardiol 2008, 51(8):856-862.
64. Platonov P.G., Mitrofanova L.B., Orshanskaya V., et al. Structural abnormalities in atrial walls are associated with presence and persistency of atrial fibrillation but not with age. JAm Coll Cardiol 2011, 58(21):2225-2232.
65. Tanaka K., Zlochiver S., Vikstrom K.L., et al. Spatial distribution of fibrosis governs fibrillation wave dynamics in the posterior left atrium during heart failure. Circ Res 2007, 101(8):839-847.
66. Higuchi K., Akkaya M., Akoum N., et al. Cardiac MRI assessment of atrial fibrosis in atrial fibrillation: implications for diagnosis and therapy. Heart 2013, [Epub ahead of print].
67. Barth A.S., Merk S., Arnoldi E., et al. Reprogramming of the human atrial transcriptome in permanent atrial fibrillation: expression of a ventricular-like genomic signature. Circ Res 2005, 96(9):1022-1029.
68. Pandit S.V., Jalife J. Rotors and the dynamics of cardiac fibrillation. Circ Res 2013, 112(5):849-862.
69. Rappel W.J., Narayan S.M. Theoretical considerations for mapping activation in human cardiac fibrillation. Chaos 2013, 23(2):023113.
70. Davidenko J.M., Pertsov A.V., Salomonsz R., et al. Stationary and drifting spiral waves of excitation in isolated cardiac muscle. Nature 1992, 355(6358):349-351.
71. Mandapati R., Skanes A., Chen J., et al. Stable microreentrant sources as a mechanism of atrial fibrillation in the isolated sheep heart. Circulation 2000, 101(2):194-199.
72. Klos M., Calvo D., Yamazaki M., et al. Atrial septopulmonary bundle of the posterior left atrium provides a substrate for atrial fibrillation initiation in a model of vagally mediated pulmonary vein tachycardia of the structurally normal heart. Circ Arrhythm Electrophysiol 2008, 1(3):175-183.
73. Moe G.K., Rheinboldt W.C., Abildskov J.A. Acomputer model of atrial fibrillation. Am Heart J 1964, 67:200-220.
74. Mines G.R. On dynamic equilibrium in the heart. JPhysiol 1913, 46(4-5):349-383.
75. Lewis T. Oliver-Sharpey Lectures on the nature of flutter and fibrillation of the auricle. Br Med J 1921, 1(3146):551-555.
76. Narayan S.M., Krummen D.E., Shivkumar K., et al. Treatment of atrial fibrillation by the ablation of localized sources: CONFIRM (Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation) trial. JAm Coll Cardiol 2012, 60:628-636.
77. Haissaguerre M., Jais P., Shah D.C., et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. NEngl J Med 1998, 339(10):659-666.
78. Narayan S.M., Bayer J.D., Lalani G., et al. Action potential dynamics explain arrhythmic vulnerability in human heart failure: a clinical and modeling study implicating abnormal calcium handling. JAm Coll Cardiol 2008, 52(22):1782-1792.
79. Rostock T., Steven D., Lutomsky B., et al. Atrial fibrillation begets atrial fibrillation in the pulmonary veins on the impact of atrial fibrillation on the electrophysiological properties of the pulmonary veins in humans. JAm Coll Cardiol 2008, 51(22):2153-2160.
80. Narayan S.M., Franz M.R., Clopton P., et al. Repolarization alternans reveals vulnerability to human atrial fibrillation. Circulation 2011, 123(25):2922-2930.
81. Markides V., Schilling R.J., Ho S.Y., et al. Characterization of left atrial activation in the intact human heart. Circulation 2003, 107(5):733-739.
82. Lalani G.G., Schricker A., Gibson M., et al. Atrial conduction slows immediately before the onset of human atrial fibrillation: a bi-atrial contact mapping study of transitions to atrial fibrillation. JAm Coll Cardiol 2012, 59(6):595-606.
83. Shivkumar K., Ellenbogen K.A., Hummel J.D., et al. Acute termination of human atrial fibrillation by identification and catheter ablation of localized rotors and sources: first multicenter experience of focal impulse and rotor modulation (FIRM) ablation. JCardiovasc Electrophysiol 2012, 23(12):1277-1285.
84. Narayan S.M., Krummen D.E., Clopton P., et al. Direct or coincidental elimination of stable rotors or focal sources may explain successful atrial fibrillation ablation: on-treatment analysis of the CONFIRM trial (Conventional Ablation for AF With or Without Focal Impulse and Rotor Modulation). JAm Coll Cardiol 2013, 62(2):138-147.
85. Owan T.E., Hodge D.O., Herges R.M., et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. NEngl J Med 2006, 355(3):251-259.
86. Bhatia R.S., Tu J.V., Lee D.S., et al. Outcome of heart failure with preserved ejection fraction in a population-based study. NEngl J Med 2006, 355(3):260-269.
87. van Heerebeek L., Borbely A., Niessen H.W., et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 2006, 113(16):1966-1973.
88. Kusunose K., Motoki H., Popovic Z.B., et al. Independent association of left atrial function with exercise capacity in patients with preserved ejection fraction. Heart 2012, 98(17):1311-1317.
89. Grace A.A., Camm A.J. Quinidine. NEngl J Med 1998, 338(1):35-45.
90. Kannankeril P., Roden D.M., Darbar D. Drug-induced long QT syndrome. Pharmacol Rev 2010, 62(4):760-781.
91. Mountantonakis S.E., Grau-Sepulveda M.V., Bhatt D.L., et al. Presence of atrial fibrillation is independently associated with adverse outcomes in patients hospitalized with heart failure: an analysis of get with the guidelines-heart failure. Circ Heart Fail 2012, 5(2):191-201.
92. Saksena S., Slee A., Waldo A.L., et al. Cardiovascular outcomes in the AFFIRM trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses. JAm Coll Cardiol 2011, 58(19):1975-1985.
93. Ahmed M.I., White M., Ekundayo O.J., et al. Ahistory of atrial fibrillation and outcomes in chronic advanced systolic heart failure: a propensity-matched study. Eur Heart J 2009, 30(16):2029-2037.
94. Dobrev D., Carlsson L., Nattel S. Novel molecular targets for atrial fibrillation therapy. Nat Rev Drug Discov 2012, 11(4):275-291.
95. Waldo A.L., Camm A.J., deRuyter H., et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 1996, 348(9019):7-12.
96. Kober L., Torp-Pedersen C., McMurray J.J., et al. Increased mortality after dronedarone therapy for severe heart failure. NEngl J Med 2008, 358(25):2678-2687.
97. Connolly S.J., Camm A.J., Halperin J.L., et al. Dronedarone in high-risk permanent atrial fibrillation. NEngl J Med 2011, 365(24):2268-2276.
98. Rudy Y., Ackerman M.J., Bers D.M., et al. Systems approach to understanding electromechanical activity in the human heart: a National Heart, Lung, and Blood Institute workshop summary. Circulation 2008, 118(11):1202-1211.
99. Trayanova N.A. Whole-heart modeling: applications to cardiac electrophysiology and electromechanics. Circ Res 2011, 108(1):113-128.
100. Thul R., Coombes S., Roderick H.L., et al. Subcellular calcium dynamics in a whole-cell model of an atrial myocyte. Proc Natl Acad Sci U S A 2012, 109(6):2150-2155.
101. Comtois P., Nattel S. Impact of tissue geometry on simulated cholinergic atrial fibrillation: a modeling study. Chaos 2011, 21(1):013108.
102. Roy D., Talajic M., Nattel S., et al. Rhythm control versus rate control for atrial fibrillation and heart failure. NEngl J Med 2008, 358(25):2667-2677.
103. Talajic M., Khairy P., Levesque S., et al. Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation. JAm Coll Cardiol 2010, 55(17):1796-1802.
104. Saumarez R.C., Chojnowska L., Derksen R., et al. Sudden death in noncoronary heart disease is associated with delayed paced ventricular activation. Circulation 2003, 107(20):2595-2600.
105. Saumarez R.C., Pytkowski M., Sterlinski M., et al. Paced ventricular electrogram fractionation predicts sudden cardiac death in hypertrophic cardiomyopathy. Eur Heart J 2008, 29(13):1653-1661.